Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 2/20 | 0.31 |
| ▸ | PYGL | P06737 | 5/20 | 0.31 |
| ▸ | PYGM | P11217 | 5/20 | 0.31 |
| ▸ | STS | P08842 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763075 | 0.93 | GAA (0.36) | MEN1KMT2APYGLPYGMSTS | |
| SCHEMBL6832233 | 0.87 | PYGL (0.30) | PYGLPYGM | |
| SCHEMBL3780385 | 0.75 | PYGL (0.39) | MEN1KMT2APYGLPYGM | |
| SCHEMBL3774611 | 0.75 | PYGL (0.39) | MEN1KMT2APYGLPYGM | |
| SCHEMBL3773910 | 0.75 | PYGL (0.39) | MEN1KMT2APYGLPYGM | |
| SCHEMBL3773445 | 0.74 | PYGL (0.38) | MEN1KMT2APYGLPYGM | |
| SCHEMBL9238137 | 0.74 | SSTR4 (0.35) | CCKBRPYGLPYGMSSTR4 | |
| SCHEMBL3769086 | 0.74 | AADAT (0.43) | MEN1KMT2APYGLPYGMTP53 | |
| SCHEMBL9109650 | 0.73 | FFAR4 (0.35) | PYGLPYGMTP53 | |
| SCHEMBL3774235 | 0.71 | HIF1A (0.36) | PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | MEN1 4474/4885KMT2A 48/4885CCKBR 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.